Immunoglobulin Products

Characteristics of Immunoglobulin Products Used to Treat Primary Immunodeficiency Diseases Booklet

IDF MAC Resolution on Product Choice for Immunoglobulin Replacement Therapy

In November 2011, the IDF Medical Advisory Committee wrote a resolution regarding formulary changes that limit a physician’s ability to determine the most appropriate immunoglobulin replacement therapy. Restricting access of subscribers to only one or two product/formulations of replacement immunoglobulin regardless of the particular product the patient may currently be receiving poses an unjustified safety risk for patients. Read the entire resolution: IDF MAC Resolution on Product Choice for Immunoglobulin Replacement Therapy – 1/26/11

The Immune Deficiency Foundation improves the diagnosis, treatment, and quality of life of people affected by primary immunodeficiency through fostering a community empowered by advocacy, education, and research.